Patents Examined by Jeffrey E. Russel
  • Patent number: 11896724
    Abstract: A wound dressing includes: a structural material formed into a dressing; at least one immunomodulatory agent associated with the dressing; and a growth factor associated with the dressing. A wound dressing kit includes: a structural material formed into a wound dressing; an immunomodulatory agent; and a growth factor composition, wherein the structural material contains the immunomodulatory agent and/or the immunomodulatory agent in a separate composition. A method of treating a wound in a tissue includes: applying an immunomodulatory agent to the wound; applying a wound dressing to the wound; and allowing the wound to heal with the immunomodulatory agent and wound dressing. The application of a growth factor can be before, during and/or after applying the wound dressing to the wound.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: February 13, 2024
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Kaushal Rege, Deepanjan Ghosh
  • Patent number: 11890326
    Abstract: The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: February 6, 2024
    Assignee: ASCENDIS PHARMA BONE DISEASES A/S
    Inventors: Kennett Sprog√łe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
  • Patent number: 11890317
    Abstract: A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: February 6, 2024
    Assignee: NovMetaPharma Co., Ltd.
    Inventors: Hoe-Yune Jung, Heon-Jong Lee, Jong-Su Jeon, Yon-Su Kim, Seung-Hee Yang, Yong-Chul Kim, Jong-Joo Moon, Hwan-Soo Yoo, Kyeong-Mi Choi
  • Patent number: 11883496
    Abstract: A physically stable compositions in the form of an injectable aqueous solution with a pH from 6.0 to 8.0, include a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: January 30, 2024
    Assignee: ADOCIA
    Inventors: You-Ping Chan, Alexandre Geissler, Romain Noel, Richard Charvet, Nicolas Laurent
  • Patent number: 11879018
    Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: January 23, 2024
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Philip Bradley, Barry L. Stoddard
  • Patent number: 11850313
    Abstract: A tissue oxygenation composition comprising (a) an oxygenated solution or a solution containing an oxygen carrier and (b) hydrogen sulfide (H2S). The disclosure also relates to methods of preserving, reperfusing and/or transfusing tissue with a tissue oxygenation composition according to the present disclosure.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: December 26, 2023
    Assignee: The London Health Sciences Centre Research Inc.
    Inventors: Alp Sener, Smriti Juriasingani
  • Patent number: 11840582
    Abstract: The present disclosure relates to a method of synthesizing cyclosporine derivatives. The method includes: providing a precursor fluid of the cyclosporine derivative, an alkaline fluid and a ClCH2OCOCl solution; premixing the precursor fluid and the alkaline fluid to obtain a premixed solution; feeding the premixed solution into a first reaction chamber, reacting to prepare a first reaction liquid; feeding the first reaction liquid into a second reaction chamber, reacting the first reaction liquid with a CO2 fluid to prepare a second reaction liquid; and reacting the second reaction liquid with the ClCH2OCOCl solution.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: December 12, 2023
    Assignee: Peking University Shenzhen Graduate School
    Inventors: Zhen Yang, Qingzhou Zhang, Fengxia Li, Chongguo Jiang, Jianxian Gong, Jun Huang, Weibin Zhang
  • Patent number: 11834481
    Abstract: A salty taste enhancing peptide derived from dry-cured ham is provided, and the amino acid sequences thereof are Asp-Leu; Phe-Met-Ser-Ala-Leu-Phe, as shown in SEQ ID NO: 1; and His-Val-Arg-Arg-Lys, as shown in SEQ ID NO: 2. The salty taste enhancing peptide in the present disclosure is of small molecular weight, features easy separation and purification, has strong salty taste enhancing effect and simple sequences, and is easy to synthesize, therefore, the salty taste enhancing peptide can be applied to the fields of food, health products, medicine and biology, and is expected to replace salt substitute products currently available on the market.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: December 5, 2023
    Assignees: Hefei University of Technology, Yunnan Agricultural University
    Inventors: Feiran Xu, Baocai Xu, Xuefeng Wang, Zhaoming Wang, Bao Zhang, Fei Ma, Ying Wu, Kai Zhou, Hui Zhou, Kezhou Cai
  • Patent number: 11834521
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: December 5, 2023
    Assignee: Bausch Health Ireland Limited
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Patent number: 11833254
    Abstract: A self-assembled discoidal PNA delivery vehicle includes a zwitterionic short chain diacyl lipid, a zwitterionic long chain diacyl lipid, a charged long chain diacyl lipid, a PEGylated lipid of the formula distearoyl phosphoethanolamine (DSPE)-PEGn-TG, and an encapsulated PNA molecule with a defined molar ratio of the zwitterionic long chain diacyl lipid and the charged long chain diacyl lipid to the short chain diacyl lipid, the molar ratio of the charged long chain diacyl lipid to the zwitterionic long chain diacyl lipid, molar % of the PEGylated lipid to all lipids, and ratio of PNA to lipid. Also described are method of self-assembling the discoidal PNA delivery vehicle and methods of enhancing cellular uptake of PNA using the discoidal PNA delivery vehicle.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: December 5, 2023
    Assignee: UNIVERSITY OF CONNECTICUT
    Inventors: Raman Bahal, Mu-Ping Nieh, Armin Tahmasbi Rad, Shipra Malik
  • Patent number: 11834482
    Abstract: Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin.
    Type: Grant
    Filed: November 3, 2021
    Date of Patent: December 5, 2023
    Assignee: FOG PHARMACEUTICALS, INC.
    Inventors: Gerard Hilinski, So Youn Shim, Matthew Reiser Patton, John Hanney McGee, Paula Cristina Ortet, Gregory L Verdine
  • Patent number: 11827684
    Abstract: Interleukin-2 (IL-2) conjugates comprising at least one or more amino acid substitutions that bias binding to the IL-2 receptor ??c dimer over binding the IL-2 receptor ???c trimer and a non-natural amino acid at or near the N-terminus conjugated to a water-soluble polymer are described. The IL-2 conjugates are useful for treatment and prevention of cell proliferation and cancer in a patient.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: November 28, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Cristina Abrahams, Edward Bowman, Xiaofan Li, Songnian Lin, Willy Solis, Ryan Stafford, Aarron Willingham, Alice Yam, Junhao Yang, Gang Yin
  • Patent number: 11827660
    Abstract: The present invention relates to a novel synthesis method to form particular molecules. These molecules have multiple uses, most notably in the field of protecting groups used throughout organic and synthetic chemistry. The disclosed method is safer, more cost- and time-effective, and more amenable to large scale production than those currently known in the art. The protecting groups synthesized are useful in GAP peptide synthesis.
    Type: Grant
    Filed: January 26, 2020
    Date of Patent: November 28, 2023
    Assignee: Sederma
    Inventor: Cole Seifert
  • Patent number: 11826398
    Abstract: Disclosed herein are ?-sheet peptides and their use for treating a bacterial infection and/or limiting bacterial biofilm formation.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: November 28, 2023
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Valerie Daggett, Alissa Bleem
  • Patent number: 11827690
    Abstract: The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 28, 2023
    Assignees: Novo Nordisk Inc., United State of America, As Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alan Thomas Remaley, Soumitra Shanker Ghosh, Madhav N. Devalaraja, Chih-Hung Lo, Denis O. Sviridov, Anna Wolska
  • Patent number: 11827910
    Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: November 28, 2023
    Assignees: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Quan Lu, Qiyu Wang, Stanley N. Cohen
  • Patent number: 11828719
    Abstract: The present invention relates to a nano-ligand for promoting cell adhesion and differentiation of stem cells and a method of promoting cell adhesion and differentiation of stem cells by using the nano-ligand, and the method of promoting cell adhesion and differentiation of stem cells according to the present invention may temporally and spatially, and reversibly control nano-ligand sliding by applying a magnetic field to a substrate including the nano-ligands, and efficiently control stem cell adhesion and differentiation ex vivo or in vivo through the magnetic-field based on spatiotemporal control.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: November 28, 2023
    Assignee: Korea University Research and Business Foundation
    Inventors: Hee-Min Kang, Chandra Khatua, Gun-Hyu Bae, Hyo-Jun Choi, Sun-Hong Min
  • Patent number: 11819533
    Abstract: The disclosure features non-irritating pharmaceutical compositions containing CD101 in pharmaceutical acceptable salt (e.g., CD101 acetate) or neutral form. The pharmaceutical compositions can be intravenously administered to a subject to treat fungal infections (e.g., candidiasis) in the subject.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: November 21, 2023
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Kenneth Bartizal, Paul Daruwala, David Hughes, Martin Patrick Hughes, Navdeep B. Malkar, Balasingam Radhakrishnan, Anuradha Vaidya
  • Patent number: 11814419
    Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: November 14, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
  • Patent number: 11806406
    Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: November 7, 2023
    Assignees: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall